180 related articles for article (PubMed ID: 33938987)
21. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Tao JJ; Schram AM; Hyman DM
Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
[TBL] [Abstract][Full Text] [Related]
22. Actionable data for precision oncology: Framing trustworthy evidence for exploratory research and clinical diagnostics.
Tempini N; Leonelli S
Soc Sci Med; 2021 Mar; 272():113760. PubMed ID: 33601250
[TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Remon J; García-Campelo R; de Álava E; Vera R; Rodríguez-Peralto JL; Rodríguez-Lescure Á; Bellosillo B; Garrido P; Rojo F; Álvarez-Alegret R
Clin Transl Oncol; 2020 Jun; 22(6):823-834. PubMed ID: 31559582
[TBL] [Abstract][Full Text] [Related]
24. [The molecular tumor board].
Missios P; Beha J; Bitzer M; Malek NP
Chirurg; 2021 Nov; 92(11):1011-1015. PubMed ID: 34406439
[TBL] [Abstract][Full Text] [Related]
25. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
[TBL] [Abstract][Full Text] [Related]
26. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.
Ziogas DE; Kyrochristos ID; Roukos DH
Expert Rev Med Devices; 2018 Jan; 15(1):1-3. PubMed ID: 29284319
[No Abstract] [Full Text] [Related]
27. [Precision oncology : How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?].
Schlomm T; Rödiger T; Graalmann J
Urologe A; 2021 Jan; 60(1):3-7. PubMed ID: 33315135
[TBL] [Abstract][Full Text] [Related]
28. [Artificial intelligence-guided precision medicine in hematological disorders].
Yokoyama K
Rinsho Ketsueki; 2020; 61(5):554-563. PubMed ID: 32507824
[TBL] [Abstract][Full Text] [Related]
29. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
30. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
31. [Implementing next-generation sequencing for precision hematology/oncology].
Maeda T
Rinsho Ketsueki; 2018; 59(10):1924-1934. PubMed ID: 30305493
[TBL] [Abstract][Full Text] [Related]
32. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
33. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
34. Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.
Khotskaya YB; Mills GB; Mills Shaw KR
Annu Rev Med; 2017 Jan; 68():113-125. PubMed ID: 27813876
[TBL] [Abstract][Full Text] [Related]
35. [From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?].
Leichsenring J; Kazdal D; Ploeger C; Allgäuer M; Endris V; Volckmar AL; Neumann O; Kirchner M; Penzel R; Rempel E; Budczies J; Schirmacher P; Fröhling S; Stenzinger A
Pathologe; 2019 May; 40(3):235-242. PubMed ID: 31089797
[TBL] [Abstract][Full Text] [Related]
36. Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants.
He MM; Li Q; Yan M; Cao H; Hu Y; He KY; Cao K; Li MM; Wang K
Genome Med; 2019 Aug; 11(1):53. PubMed ID: 31443733
[TBL] [Abstract][Full Text] [Related]
37. Best Practice for Clinical Somatic Variant Interpretation and Reporting.
Schubert J; Wu J; Li MM; Cao K
Clin Lab Med; 2022 Sep; 42(3):423-434. PubMed ID: 36150821
[TBL] [Abstract][Full Text] [Related]
38. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
39. Genomics-Enabled Precision Medicine for Cancer.
Roos A; Byron SA
Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
[TBL] [Abstract][Full Text] [Related]
40. [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].
Holch JW; Westphalen CB; Hiddemann W; Heinemann V; Jung A; Metzeler KH
Dtsch Med Wochenschr; 2017 Nov; 142(22):1676-1684. PubMed ID: 29078213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
